

T G A

**THERAPEUTIC
GOODS
ADMINISTRATION**

PO Box 100 Woden ACT 2606 Australia
Telephone: (02) 6232 8444 Facsimile: (02) 6232 8241



FACSIMILE

Date:	20 November 2001	Total pages:	1
TO:	GlaxoSmithKline Australia Ltd	Telephone:	[REDACTED]
ATTENTION:	[REDACTED]	Facsimile:	[REDACTED]
Regarding:	Request for further information – AU Army Safety Study trial		
FROM:	Rhonda Whybrow Clinical Trials Notification Officer	Telephone:	02 6232 8106
Branch/Div.:	Drug Safety & Evaluation Therapeutic Goods Administration	Facsimile:	02 6232 8112

If you do not receive all pages, please telephone the sender immediately

MESSAGE

Dear [REDACTED]

I wish to acknowledge receipt of the Serious Adverse Event [REDACTED] which was received by the Therapeutic Goods Administration on 16 July 2001.

I have been asked to obtain additional information on the outcome or progress of this event.

Patient Initials: [REDACTED]
DOB: [REDACTED]
Country: East Timor

It would be appreciated if you could fax this information to me as soon as possible on (02) 6232 8112.

If you wish to discuss this matter further please contact me on (02) 6232 8106.

Regards

Rhonda Whybrow
Clinical Trials Officer
Experimental Drugs Section
Drug Safety and Evaluation Branch